Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
Ultomiris transforms the treatment landscape for AQP4 Ab+ NMOSD patients, with potential to eliminate relapses and improve outcomes.Ultomiris (ravulizumab) has been approved in the European Union (EU) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).[1] The approval by the European Commission follows the positive opinion of the